Morningstar Investor users sign in here.

Video

Is the 60/40 portfolio dead?

Do investors need to look beyond stocks and bonds in the current environment? Morningstar's Annika Bradley speaks with AustralianSuper CIO Mark Delaney. 


2022 was a sobering year for those who had supported the 60/40 approach - a balanced portfolio that places 60% of its assets in stocks and 40% in bonds.

Morningstar's 2023 Diversification Landscape report investigates how a continued period of higher inflation might affect the link between stocks and bonds. It concludes that if inflation remains above average for an extended period, Treasuries and other high-quality bonds might be less reliable diversifiers.

So, do investors need to look beyond stocks and bonds?

Morningstar's Annika Bradley asked AustralianSuper chief investment officer Mark Delaney at the 2023 Morningstar Investment Conference in Sydney.

Transcript: 


Annika Bradley
: So let's start with the portfolio and this notion that the 60-40 portfolio is dead. So that is investors need to look beyond stocks and bonds. BlackRock are calling for an increased allocation to alternatives. Vanguard are unsurprisingly staying the course at this point. Mark, from your perspective, is the 60-40 portfolio dead. Do investors need to look beyond that portfolio?

Mark Delaney: Hi everybody, thank you for having me. It's good to see everybody here and those online. I don't think it's really dead. We've done some work on this and the argument really is that high inflation or higher inflation is going to make it harder for bonds to work and more difficult for stocks, and there's a degree of truth in that. More than likely higher inflation if it manifests itself over the medium term will result in lower returns in all the investment classes. And the absolute total return comes down, but the relative ranking of asset class returns probably won't change that much, i.e. on a 10-year view stocks will beat bonds, you know, bonds will do better than cash, et cetera. It's just instead of getting like AustralianSuper's balanced plans done, I think 8 in the quarter over the last 20 years, you won't be getting 8 in the quarter you'll be getting 6.5.

Bradley: And what about alternatives and private markets, do you see that as a core part of evolving portfolio?

Delaney: That's really the endowment model, I mean endowments were the first ones to adopt this, and then the Canadian pension plans went there. And the Australian, particularly the industry funds, were very early adopters of infrastructure and some extent private equity. There's a big role for private assets in portfolios, if they can be well executed. They have much more operational leverage than in a public market. And you can get some businesses which have a much greater growth potential. So the combination of both allows you to get much better returns. They're no longer as cheap as what they used to be. So you used to be able to buy private businesses at a discount to publics, you can't do that any longer, but the leverage aspect, operational leverage, particularly in private equity is really substantial. And if you think back to the airports they were, pre-COVID probably the best returning investment over 25 years. But when they were privatised, they were just sold on landing revenue. They weren't sold on any revenue from the car parks, from the shops and whatever. So with all these private businesses, it's not so much what the revenue is today, but what the revenue can be in the future, so it does require active management, but I think they're a core part of your portfolio if you can do it well.



© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Bank results: the winners and losers
Video

Bank results: the winners and losers

Morningstar analyst Nathan Zaia explains how the banks did and what the future holds.
How to deal with financial stress
Video

How to deal with financial stress

More high-income earners are now also experiencing financial stress. We go through practical ways to reduce it
UniSuper CIO John Pearce on why the 60/40 portfolio is far from dead
Video

UniSuper CIO John Pearce on why the 60/40 portfolio is far from dead

The $130 Billion SuperFund Manager also talks about how he sees risk, his recent investments, and why history isn’t a good guide to the future.
Incitec Pivot: explosive upside ahead?
Video

Incitec Pivot: explosive upside ahead?

Morningstar analyst Mark Taylor believes imminent growth in explosives earnings could lift sentiment.
Why Morningstar see opportunities in coal stocks
Video

Why Morningstar see opportunities in coal stocks

Analyst Jon Mills explains why he’s recently increased fair value estimates for Australian coal companies.
Is the sharp fall in ResMed's share price justified?
Video

Is the sharp fall in ResMed's share price justified?

The potential for weight loss drugs to impact the sleep apnea giant has weighed on the share price, though Morningstar analyst Shane Ponraj thinks...